PharmacoEconomics

, Volume 32, Issue 7, pp 639–650 | Cite as

A Review of the Economics of Treating Clostridium difficile Infection

  • Kari A. Mergenhagen
  • Amy L. Wojciechowski
  • Joseph A. Paladino
Review Article

Abstract

Clostridium difficile infection (CDI) is a costly result of antibiotic use, responsible for an estimated 14,000 deaths annually in the USA according to the Centers for Disease Control and Prevention. Annual costs attributable to CDI are in excess of $US1 billion. This review summarizes appropriate utilization of prevention and treatment methods for CDI that have the potential to reduce the economic and humanistic costs of the disease. Some cost-effective strategies to prevent CDI include screening and isolation of hospital admissions based on C. difficile carriage to reduce transmission in the inpatient setting, and probiotics, which are potentially efficacious in preventing CDI in the appropriate patient population. The most extensively studied agents for treatment of CDI are metronidazole, vancomycin, and fidaxomicin. Most economic comparisons between metronidazole and vancomycin favor vancomycin, especially with the emergence of metronidazole-resistant C. difficile strains. Metronidazole can only be recommended for mild disease. Moderate to severe CDI should be treated with vancomycin, preferably the compounded oral solution, which provides the most cost-effective therapeutic option. Fidaxomicin offers a clinically effective and potentially cost-effective alternative for treating moderate CDI in patients who do not have the NAP1/BI/027 strain of C. difficile. Probiotics and fecal microbiota transplant have variable efficacy and the US FDA does not currently regulate the content; the potential economic advantages of these treatment modalities are currently unknown.

Notes

Acknowledgments

This manuscript is the result of work supported in part by resources and the use of facilities at the Veterans Affairs Western New York Healthcare System. The contents of this manuscript are not intended to represent the views of the Department of Veterans Affairs or the US Government.

Kari Mergenhagen has no relevant conflicts of interest to disclose.

Amy Wojciechowski has no relevant conflicts of interest to disclose.

Joseph Paladino has no relevant conflicts of interest to disclose.

Kari Mergenhagen and Amy Wojciechowski performed the initial literature search, wrote and prepared the manuscript for submission, and responded to reviewer comments and requests for revisions. Joseph Paladino contributed to the conceptualization and design of the review article and helped with editing and revisions of the manuscript. Senior author, Joseph Paladino, serves as the overall guarantor of the content of this manuscript.

References

  1. 1.
    Gerding DN, Muto CA, Owens RC Jr. Treatment of Clostridium difficile infection. Clin Infect Dis. 2008;46(Suppl 1):S32–42. doi: 10.1086/521860.CrossRefPubMedGoogle Scholar
  2. 2.
    Frieden T. Antibiotic resistance threats in the United States. 2013. http://www.cdc.gov/drugresistance/threat-report-2013/, editor. CDC.gov2013.
  3. 3.
    McFarland LV, Mulligan ME, Kwok RY, Stamm WE. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med. 1989;320(4):204–10. doi: 10.1056/NEJM198901263200402.CrossRefPubMedGoogle Scholar
  4. 4.
    Riggs MM, Sethi AK, Zabarsky TF, Eckstein EC, Jump RL, Donskey CJ. Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic Clostridium difficile strains among long-term care facility residents. Clin Infect Dis. 2007;45(8):992–8. doi: 10.1086/521854.CrossRefPubMedGoogle Scholar
  5. 5.
    Gerding DN. Clostridium difficile 30 years on: what has, or has not, changed and why? Int J Antimicrob Agents. 2009;33(Suppl 1):S2–8. doi: 10.1016/S0924-8579(09)70008-1.CrossRefPubMedGoogle Scholar
  6. 6.
    Owens RC Jr, Donskey CJ, Gaynes RP, Loo VG, Muto CA. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis. 2008;46(Suppl 1):S19–31. doi: 10.1086/521859.CrossRefPubMedGoogle Scholar
  7. 7.
    McDonald LC, Killgore GE, Thompson A, Owens RC Jr, Kazakova SV, Sambol SP, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med. 2005;353(23):2433–41. doi: 10.1056/NEJMoa051590.CrossRefPubMedGoogle Scholar
  8. 8.
    Muto CA, Pokrywka M, Shutt K, Mendelsohn AB, Nouri K, Posey K, et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol. 2005;26(3):273–80. doi: 10.1086/502539.CrossRefPubMedGoogle Scholar
  9. 9.
    Gaynes R, Rimland D, Killum E, Lowery HK, Johnson TM 2nd, Killgore G, et al. Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use. Clin Infect Dis. 2004;38(5):640–5. doi: 10.1086/381551.CrossRefPubMedGoogle Scholar
  10. 10.
    Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med. 2005;353(23):2442–9. doi: 10.1056/NEJMoa051639.CrossRefPubMedGoogle Scholar
  11. 11.
    Johnson S, Samore MH, Farrow KA, Killgore GE, Tenover FC, Lyras D, et al. Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals. N Engl J Med. 1999;341(22):1645–51. doi: 10.1056/NEJM199911253412203.CrossRefPubMedGoogle Scholar
  12. 12.
    Pepin J, Valiquette L, Cossette B. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ. 2005;173(9):1037–42. doi: 10.1503/cmaj.050978.CrossRefPubMedCentralPubMedGoogle Scholar
  13. 13.
    Warny M, Pepin J, Fang A, Killgore G, Thompson A, Brazier J, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet. 2005;366(9491):1079–84. doi: 10.1016/S0140-6736(05)67420-X.CrossRefPubMedGoogle Scholar
  14. 14.
    Pepin J, Alary ME, Valiquette L, Raiche E, Ruel J, Fulop K, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis. 2005;40(11):1591–7. doi: 10.1086/430315.CrossRefPubMedGoogle Scholar
  15. 15.
    Gerding DN, Johnson S. Management of Clostridium difficile infection: thinking inside and outside the box. Clin Infect Dis. 2010;51(11):1306–13. doi: 10.1086/657116.CrossRefPubMedGoogle Scholar
  16. 16.
    Gerding DN, Muto CA, Owens RC Jr. Measures to control and prevent Clostridium difficile infection. Clin Infect Dis. 2008;46(Suppl 1):S43–9. doi: 10.1086/521861.CrossRefPubMedGoogle Scholar
  17. 17.
    Loo VG, Bourgault AM, Poirier L, Lamothe F, Michaud S, Turgeon N, et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med. 2011;365(18):1693–703. doi: 10.1056/NEJMoa1012413.CrossRefPubMedGoogle Scholar
  18. 18.
    Eyre DW, Cule ML, Wilson DJ, Griffiths D, Vaughan A, O’Connor L, et al. Diverse sources of C. difficile infection identified on whole-genome sequencing. N Engl J Med. 2013;369(13):1195–205. doi: 10.1056/NEJMoa1216064.CrossRefPubMedGoogle Scholar
  19. 19.
    Al-Tureihi FI, Hassoun A, Wolf-Klein G, Isenberg H. Albumin, length of stay, and proton pump inhibitors: key factors in Clostridium difficile-associated disease in nursing home patients. J Am Med Dir Assoc. 2005;6(2):105–8. doi: 10.1016/j.jamda.2005.01.003.CrossRefPubMedGoogle Scholar
  20. 20.
    Cunningham R, Dale B, Undy B, Gaunt N. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J Hosp Infect. 2003;54(3):243–5.CrossRefPubMedGoogle Scholar
  21. 21.
    Dial S, Alrasadi K, Manoukian C, Huang A, Menzies D. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ. 2004;171(1):33–8.CrossRefPubMedCentralPubMedGoogle Scholar
  22. 22.
    McFarland LV, Surawicz CM, Stamm WE. Risk factors for Clostridium difficile carriage and C. difficile-associated diarrhea in a cohort of hospitalized patients. J Infect Dis. 1990;162(3):678–84.CrossRefPubMedGoogle Scholar
  23. 23.
    Dubberke ER, Reske KA, Olsen MA, McMullen KM, Mayfield JL, McDonald LC, et al. Evaluation of Clostridium difficile-associated disease pressure as a risk factor for C. difficile-associated disease. Arch Intern Med. 2007;167(10):1092–7. doi: 10.1001/archinte.167.10.1092.CrossRefPubMedGoogle Scholar
  24. 24.
    Chitnis AS, Holzbauer SM, Belflower RM, Winston LG, Bamberg WM, Lyons C, et al. Epidemiology of community-associated Clostridium difficile infection, 2009 through 2011. JAMA Intern Med. 2013;173(14):1359–67. doi: 10.1001/jamainternmed.2013.7056.CrossRefPubMedGoogle Scholar
  25. 25.
    Kyne L, Hamel MB, Polavaram R, Kelly CP. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis. 2002;34(3):346–53. doi: 10.1086/338260.CrossRefPubMedGoogle Scholar
  26. 26.
    Dubberke ER, Reske KA, Olsen MA, McDonald LC, Fraser VJ. Short- and long-term attributable costs of Clostridium difficile-associated disease in nonsurgical inpatients. Clin Infect Dis. 2008;46(4):497–504. doi: 10.1086/526530.CrossRefPubMedGoogle Scholar
  27. 27.
    Song X, Bartlett JG, Speck K, Naegeli A, Carroll K, Perl TM. Rising economic impact of Clostridium difficile-associated disease in adult hospitalized patient population. Infect Control Hosp Epidemiol. 2008;29(9):823–8. doi: 10.1086/588756.CrossRefPubMedGoogle Scholar
  28. 28.
    O’Brien JA, Lahue BJ, Caro JJ, Davidson DM. The emerging infectious challenge of Clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences. Infect Control Hosp Epidemiol. 2007;28(11):1219–27. doi: 10.1086/522676.CrossRefPubMedGoogle Scholar
  29. 29.
    Paladino JA, Schentag JJ. The economics of Clostridium difficile-associated disease for providers and payers. Clin Infect Dis. 2008;46(4):505–6. doi: 10.1086/526531.CrossRefPubMedGoogle Scholar
  30. 30.
    Kuijper EJ, Coignard B, Tull P, difficile ESGfC, States EUM, European Centre for Disease P et al. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect. 2006;12(Suppl 6):2–18. doi: 10.1111/j.1469-0691.2006.01580.x.
  31. 31.
    Barbut F, Cornely O, Fitzpatrick F, Kuijper EJ, Nagy E, Rupnik M et al. Clostridium difficile infection in Europe: A CDI Europe Report; 2013.Google Scholar
  32. 32.
    Magalini S, Pepe G, Panunzi S, Spada PL, De Gaetano A, Gui D. An economic evaluation of Clostridium difficile infection management in an Italian hospital environment. Eur Rev Med Pharmacol Sci. 2012;16(15):2136–41.PubMedGoogle Scholar
  33. 33.
    Wiegand PN, Nathwani D, Wilcox MH, Stephens J, Shelbaya A, Haider S. Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of healthcare-facility-acquired infection. J Hosp Infect. 2012;81(1):1–14. doi: 10.1016/j.jhin.2012.02.004.CrossRefPubMedGoogle Scholar
  34. 34.
    Dubberke ER, Olsen MA. Burden of Clostridium difficile on the healthcare system. Clin Infect Dis. 2012;55(Suppl 2):S88–92. doi: 10.1093/cid/cis335.CrossRefPubMedCentralPubMedGoogle Scholar
  35. 35.
    McGlone SM, Bailey RR, Zimmer SM, Popovich MJ, Tian Y, Ufberg P, et al. The economic burden of Clostridium difficile. Clin Microbiol Infect. 2012;18(3):282–9. doi: 10.1111/j.1469-0691.2011.03571.x.CrossRefPubMedCentralPubMedGoogle Scholar
  36. 36.
    Shupo F, Dorey J, Aballea S, McGarry T, Odeyemi II, Toumi M. PIN75 health-related quality of life of Clostridium difficile infection: a methodological contribution to direct utility elicitation by TTO. Value Health. 2012;15(7):A399. doi:http://dx.doi.org/10.1016/j.jval.2012.08.1142.
  37. 37.
    Climo MW, Israel DS, Wong ES, Williams D, Coudron P, Markowitz SM. Hospital-wide restriction of clindamycin: effect on the incidence of Clostridium difficile-associated diarrhea and cost. Ann Intern Med. 1998;128(12 Pt 1):989–95.CrossRefPubMedGoogle Scholar
  38. 38.
    Carling P, Fung T, Killion A, Terrin N, Barza M. Favorable impact of a multidisciplinary antibiotic management program conducted during 7 years. Infect Control Hosp Epidemiol. 2003;24(9):699–706. doi: 10.1086/502278.CrossRefPubMedGoogle Scholar
  39. 39.
    Allegranzi B, Pittet D. Role of hand hygiene in healthcare-associated infection prevention. J Hosp Infect. 2009;73(4):305–15. doi: 10.1016/j.jhin.2009.04.019.CrossRefPubMedGoogle Scholar
  40. 40.
    Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31(5):431–55. doi: 10.1086/651706.CrossRefPubMedGoogle Scholar
  41. 41.
    Surawicz CM, Brandt LJ, Binion DG, Ananthakrishnan AN, Curry SR, Gilligan PH et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013;108(4):478–98; quiz 99. doi: 10.1038/ajg.2013.4.
  42. 42.
    Debast SB, Bauer MP, Kuijper EJ, on behalf of the Committee. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect. 2014;20(Suppl 2):1–26. doi: 10.1111/1469-0691.12418.CrossRefPubMedGoogle Scholar
  43. 43.
    Al-Nassir WN, Sethi AK, Li Y, Pultz MJ, Riggs MM, Donskey CJ. Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease. Antimicrob Agents Chemother. 2008;52(7):2403–6. doi: 10.1128/AAC.00090-08.CrossRefPubMedCentralPubMedGoogle Scholar
  44. 44.
    Vardakas KZ, Polyzos KA, Patouni K, Rafailidis PI, Samonis G, Falagas ME. Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: a systematic review of the evidence. Int J Antimicrob Agents. 2012;40(1):1–8. doi: 10.1016/j.ijantimicag.2012.01.004.CrossRefPubMedGoogle Scholar
  45. 45.
    Al-Nassir WN, Sethi AK, Nerandzic MM, Bobulsky GS, Jump RL, Donskey CJ. Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin. Clin Infect Dis. 2008;47(1):56–62. doi: 10.1086/588293.CrossRefPubMedGoogle Scholar
  46. 46.
    DuPont HL, Garey K, Caeiro JP, Jiang ZD. New advances in Clostridium difficile infection: changing epidemiology, diagnosis, treatment and control. Current Opin Infect Dis. 2008;21(5):500–7. doi: 10.1097/QCO.0b013e32830f9397.CrossRefGoogle Scholar
  47. 47.
    Al-Eidan FA, McElnay JC, Scott MG, Kearney MP, Corrigan J, McConnell JB. Use of a treatment protocol in the management of community-acquired lower respiratory tract infection. J Antimicrob Chemother. 2000;45(3):387–94.CrossRefPubMedGoogle Scholar
  48. 48.
    Lahue BJ, Davidson DM. Metronidazole and vancomycin outcomes for Clostridium difficile-associated diarrhoea in a US hospital database. In: 17th European Congress of Clinical Microbiology and Infectious Diseases; Munich, Germany: European Society of Clinical Microbiology and Infectious Diseases; 2007.Google Scholar
  49. 49.
    Al-Eidan FA, McElnay JC, Scott MG, Kearney MP. Clostridium difficile-associated diarrhoea in hospitalised patients. J Clin Phar Ther. 2000;25(2):101–9.CrossRefGoogle Scholar
  50. 50.
    Thomas KL Holmes K, Jackson BR, Go M, Fang JC, Peterson KA. A cost comparison of metronidazole and vancomycin in the treatment of Clostridium difficile associated diarrhea [abstract]. Am J Gastroenterol. 2007;102(Suppl 2):S268.Google Scholar
  51. 51.
    Perras C, Tsakonas E, Ndegwa S, Conly J, Valiquette L, Farrah K. Vancomycin or metronidazole for treatment of Clostridium difficile infection: clinical and economic analyses. CADTH Health Technology Assessments. Ottawa (ON); 2011.Google Scholar
  52. 52.
    Teasley DG, Gerding DN, Olson MM, Peterson LR, Gebhard RL, Schwartz MJ, et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium difficile-associated diarrhoea and colitis. Lancet. 1983;2(8358):1043–6.CrossRefPubMedGoogle Scholar
  53. 53.
    Butterworth SA, Koppert E, Clarke A, Wiggs B, MacFarlane JK. Recent trends in diagnosis and treatment of Clostridium difficile in a tertiary care facility. Am J Surg. 1998;175(5):403–7. doi: 10.1016/S0002-9610(98)00058-0.CrossRefPubMedGoogle Scholar
  54. 54.
    Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis. 2007;45(3):302–7. doi: 10.1086/519265.CrossRefPubMedGoogle Scholar
  55. 55.
    Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011;364(5):422–31. doi: 10.1056/NEJMoa0910812.CrossRefPubMedGoogle Scholar
  56. 56.
    Cornely OA, Crook DW, Esposito R, Poirier A, Somero MS, Weiss K, et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis. 2012;12(4):281–9. doi: 10.1016/S1473-3099(11)70374-7.CrossRefPubMedGoogle Scholar
  57. 57.
    Bartsch SM, Umscheid CA, Fishman N, Lee BY. Is fidaxomicin worth the cost? An economic analysis. Clin Infect Dis. 2013;57(4):555–61. doi: 10.1093/cid/cit346.CrossRefPubMedGoogle Scholar
  58. 58.
    Petrella LA, Sambol SP, Cheknis A, Nagaro K, Kean Y, Sears PS, et al. Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C. difficile BI strain. Clin Infect Dis. 2012;55(3):351–7. doi: 10.1093/cid/cis430.CrossRefPubMedCentralPubMedGoogle Scholar
  59. 59.
    Chitnis AS, Holzbauer SM, Belflower RM, Winston LG, Bamberg WM, Lyons C, et al. Epidemiology of community-associated Clostridium difficile infection, 2009 through 2011. JAMA Intern Med. 2013;173(14):1359–67. doi: 10.1001/jamainternmed.2013.7056.CrossRefPubMedGoogle Scholar
  60. 60.
    Simon MS. Cost-effectiveness of fidaxomicin for Clostridium difficile treatment. Clin Infect Dis. 2014;58(4):603. doi: 10.1093/cid/cit772.CrossRefPubMedGoogle Scholar
  61. 61.
    Hartzema AG, Chen C. Is fidaxomicin worth the cost? The verdict is still out! Clin Infect Dis. 2014;58(4):604–5. doi: 10.1093/cid/cit774.CrossRefPubMedGoogle Scholar
  62. 62.
    Shah H, Doyle JJ, Belletti DA. An economic analysis: is fidaxomicin worth the cost? Clin Infect Dis. 2014;58(4):603–4. doi: 10.1093/cid/cit773.CrossRefPubMedCentralPubMedGoogle Scholar
  63. 63.
    Stranges PM, Hutton DW, Collins CD. Cost-effectiveness analysis evaluating fidaxomicin versus oral vancomycin for the treatment of Clostridium difficile infection in the United States. Value Health. 2013;16(2):297–304. doi: 10.1016/j.jval.2012.11.004.CrossRefPubMedGoogle Scholar
  64. 64.
    Madkour N, Bounthavong M, Hsu DI. PGI21 a comparison of the cost-effectiveness of fidaxomicin, metronidazole, and vancomycin, in the treatment of Clostridium difficile-associated disease. Value Health. 2012;15(4):A138–9.CrossRefGoogle Scholar
  65. 65.
    Alowayesh MS, Holdford D, Harpe SE. PIN35 decision analysis model evaluating the cost-effectiveness of fidaxomicin and vancomycin in the treatment of Clostridium difficile infection (CDI) from a hospital perspective. Value Health. 2012;15(4):A243.CrossRefGoogle Scholar
  66. 66.
    RED BOOK Online® [database on the Internet]. Truven health analytics. http://www.micromedexsolutions.com. Accessed 30 Sept 2013.
  67. 67.
    Surawicz CM, Brandt LJ, Binion DG, Ananthakrishnan AN, Curry SR, Gilligan PH et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013;108(4):478–98; quiz 99. doi: 10.1038/ajg.2013.4.
  68. 68.
    Guo B, Harstall C, Nguyen T, Ohinmaa A. Fecal transplantation for the treatment of Clostridium difficile-associated disease or ulcerative colitis. Institute of Health Economics. 2011; Alberta STE Report 1–60.Google Scholar
  69. 69.
    Faecal microbiota transplant for recurrent Clostridium difficile infection. NICE interventional procedure guidance 485. 2014. http://guidance.nice.org.uk/ipg485.
  70. 70.
    Louie T, Cannon K, O’grady H, Wu K, Ward L, editors. Fecal microbiome transplantation (FMT) via oral fecal microbial capsules for recurrent Clostridium difficile infection (rCDI). ID Week 2013; October 3, 2013; San Francisco, CA.Google Scholar
  71. 71.
    Borody TJ, Warren EF, Leis SM, Surace R, Ashman O, Siarakas S. Bacteriotherapy using fecal flora: toying with human motions. J Clin Gastroenterol. 2004;38(6):475–83.CrossRefPubMedGoogle Scholar
  72. 72.
    Rogers GB, Bruce KD. Challenges and opportunities for faecal microbiota transplantation therapy. Epidemiol Infect. 2013;141(11):2235–42. doi: 10.1017/S0950268813001362.CrossRefPubMedGoogle Scholar
  73. 73.
    Brandt LJ. American Journal of Gastroenterology Lecture: intestinal microbiota and the role of fecal microbiota transplant (FMT) in treatment of C. difficile infection. Am J Gastroenterol. 2013;108(2):177–85. doi: 10.1038/ajg.2012.450.CrossRefPubMedGoogle Scholar
  74. 74.
    van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368(5):407–15. doi: 10.1056/NEJMoa1205037.CrossRefPubMedGoogle Scholar
  75. 75.
    Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis. 2011;53(10):994–1002. doi: 10.1093/cid/cir632.CrossRefPubMedGoogle Scholar
  76. 76.
    Mattila E, Uusitalo-Seppala R, Wuorela M, Lehtola L, Nurmi H, Ristikankare M, et al. Fecal transplantation, through colonoscopy, is effective therapy for recurrent Clostridium difficile infection. Gastroenterology. 2012;142(3):490–6. doi: 10.1053/j.gastro.2011.11.037.CrossRefPubMedGoogle Scholar
  77. 77.
    Brandt LJ, Aroniadis OC, Mellow M, Kanatzar A, Kelly C, Park T, et al. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am J Gastroenterol. 2012;107(7):1079–87. doi: 10.1038/ajg.2012.60.CrossRefPubMedGoogle Scholar
  78. 78.
    Avery L, Hasan M. Fecal bacteriotherapy for Clostridium difficile infections—its time has come. Clin Microbiol Newslett. 2013;35(15):119–24.CrossRefGoogle Scholar
  79. 79.
    Aas J, Gessert CE, Bakken JS. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis. 2003;36(5):580–5. doi: 10.1086/367657.CrossRefPubMedGoogle Scholar
  80. 80.
    Bakken JS, Borody T, Brandt LJ, Brill JV, Demarco DC, Franzos MA, et al. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol. 2011;9(12):1044–9. doi: 10.1016/j.cgh.2011.08.014.CrossRefPubMedCentralPubMedGoogle Scholar
  81. 81.
    Johnson S, Schriever C, Galang M, Kelly CP, Gerding DN. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis. 2007;44(6):846–8. doi: 10.1086/511870.CrossRefPubMedGoogle Scholar
  82. 82.
    Garey KW, Ghantoji SS, Shah DN, Habib M, Arora V, Jiang ZD, et al. A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. J Antimicrob Chemother. 2011;66(12):2850–5. doi: 10.1093/jac/dkr377.CrossRefPubMedGoogle Scholar
  83. 83.
    Mattila E, Arkkila P, Mattila PS, Tarkka E, Tissari P, Anttila VJ. Rifaximin in the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther. 2013;37(1):122–8. doi: 10.1111/apt.12111.CrossRefPubMedGoogle Scholar
  84. 84.
    Johnson S, Schriever C, Patel U, Patel T, Hecht DW, Gerding DN. Rifaximin redux: treatment of recurrent Clostridium difficile infections with rifaximin immediately post-vancomycin treatment. Anaerobe. 2009;15(6):290–1. doi: 10.1016/j.anaerobe.2009.08.004.CrossRefPubMedGoogle Scholar
  85. 85.
    O’Connor JR, Galang MA, Sambol SP, Hecht DW, Vedantam G, Gerding DN, et al. Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile. Antimicrob Agents Chemother. 2008;52(8):2813–7. doi: 10.1128/AAC.00342-08.CrossRefPubMedCentralPubMedGoogle Scholar
  86. 86.
    Miller MA, Blanchette R, Spigaglia P, Barbanti F, Mastrantonio P. Divergent rifamycin susceptibilities of Clostridium difficile strains in Canada and Italy and predictive accuracy of rifampin Etest for rifamycin resistance. J Clin Microbiol. 2011;49(12):4319–21. doi: 10.1128/JCM.05100-11.CrossRefPubMedCentralPubMedGoogle Scholar
  87. 87.
    Curry SR, Marsh JW, Shutt KA, Muto CA, O’Leary MM, Saul MI, et al. High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital. Clin Infect Dis. 2009;48(4):425–9. doi: 10.1086/596315.CrossRefPubMedCentralPubMedGoogle Scholar
  88. 88.
    Surawicz CM. Role of probiotics in antibiotic-associated diarrhea, Clostridium difficile-associated diarrhea, and recurrent Clostridium difficile-associated diarrhea. J Clin Gastroenterol. 2008;42(Suppl 2):S64–70. doi: 10.1097/MCG.0b013e3181646d09.CrossRefPubMedGoogle Scholar
  89. 89.
    Goldenberg JZ, Ma SS, Saxton JD, Martzen MR, Vandvik PO, Thorlund K, et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev. 2013;5:CD006095. doi: 10.1002/14651858.CD006095.pub3.
  90. 90.
    Allen SJ, Wareham K, Wang D, Bradley C, Hutchings H, Harris W, et al. Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2013;. doi: 10.1016/S0140-6736(13)61218-0.Google Scholar
  91. 91.
    Belet N, Dalgic N, Oncel S, Ciftci E, Ince E, Guriz H, et al. Catheter-related fungemia caused by Saccharomyces cerevisiae in a newborn. Pediatr Infect Dis J. 2005;24(12):1125.CrossRefPubMedGoogle Scholar
  92. 92.
    Boyle RJ, Robins-Browne RM, Tang ML. Probiotic use in clinical practice: what are the risks? Am J Clin Nutr. 2006;83(6):1256–64 quiz 446–447.PubMedGoogle Scholar
  93. 93.
    Munoz P, Bouza E, Cuenca-Estrella M, Eiros JM, Perez MJ, Sanchez-Somolinos M, et al. Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis. 2005;40(11):1625–34. doi: 10.1086/429916.CrossRefPubMedGoogle Scholar
  94. 94.
    Salminen MK, Tynkkynen S, Rautelin H, Saxelin M, Vaara M, Ruutu P, et al. Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland. Clin Infect Dis. 2002;35(10):1155–60. doi: 10.1086/342912.CrossRefPubMedGoogle Scholar
  95. 95.
    Kelesidis T, Pothoulakis C. Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders. Therap Adv Gastroenterol. 2012;5(2):111–25. doi: 10.1177/1756283X11428502.CrossRefPubMedCentralPubMedGoogle Scholar
  96. 96.
    Salminen MK, Rautelin H, Tynkkynen S, Poussa T, Saxelin M, Valtonen V, et al. Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG. Clin Infect Dis. 2004;38(1):62–9. doi: 10.1086/380455.CrossRefPubMedGoogle Scholar
  97. 97.
    Curry SR, Schlackman JL, Hamilton TM, Henderson TK, Brown NT, Marsh JW, et al. Perirectal swab surveillance for Clostridium difficile by use of selective broth preamplification and real-time PCR detection of tcdB. J Clin Microbiol. 2011;49(11):3788–93. doi: 10.1128/JCM.00679-11.CrossRefPubMedCentralPubMedGoogle Scholar
  98. 98.
    Bartsch SM, Curry SR, Harrison LH, Lee BY. The potential economic value of screening hospital admissions for Clostridium difficile. Eur J Clin Microbiol Infect Dis. 2012;31(11):3163–71. doi: 10.1007/s10096-012-1681-z.CrossRefPubMedCentralPubMedGoogle Scholar
  99. 99.
    Clabots CR, Johnson S, Olson MM, Peterson LR, Gerding DN. Acquisition of Clostridium difficile by hospitalized patients: evidence for colonized new admissions as a source of infection. J Infect Dis. 1992;166(3):561–7.CrossRefPubMedGoogle Scholar
  100. 100.
    Johnson S, Homann SR, Bettin KM, Quick JN, Clabots CR, Peterson LR, et al. Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo-controlled trial. Ann Intern Med. 1992;117(4):297–302.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland (outside the USA) 2014

Authors and Affiliations

  • Kari A. Mergenhagen
    • 1
  • Amy L. Wojciechowski
    • 1
  • Joseph A. Paladino
    • 2
    • 3
  1. 1.Veterans Affairs Western New York Healthcare SystemBuffaloUSA
  2. 2.University at Buffalo School of Pharmacy and Pharmaceutical SciencesBuffaloUSA
  3. 3.CPL Associates, LLCBuffaloUSA

Personalised recommendations